Brittanie M Millang

Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.

V. Rusch, M. Bains, K. Goodman, 2016, Journal of gastrointestinal oncology.

Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma

N. Schultz, G. Abou-Alfa, H. Ren, 2022, Targeted Oncology.

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).

N. Schultz, C. Chong, D. Solit, 2019, Journal of Clinical Oncology.

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.

B. Taylor, N. Schultz, D. Solit, 2020, The Lancet. Oncology.

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

G. Abou-Alfa, J. Harding, M. Capanu, 2020, Cancer medicine.

Emergence of RTK/RAS/PI3K pathway alterations in trastuzumab-refractory HER2-positive esophagogastric (EG) tumors.

B. Taylor, N. Schultz, M. Berger, 2016 .